Heat Biologics (NASDAQ:HTBX) announced the issuance of US Patent No. 10,758,611 for its gp96 platform combined with a T cell costimulatory agonist. This novel therapy has shown superior pre-clinical activity compared to traditional systemic approaches. The combination offers benefits like enhanced memory T cell response and reduced systemic toxicity. CEO Jeff Wolf highlighted the potential breakthrough in treating cancer and infectious diseases, including COVID-19. Current trials are underway for gp96 (HS-110) and OX40L (HS-130), with plans for more updates ahead.
Heat Biologics has published positive preclinical results for its gp96-based COVID-19 vaccine, highlighting its ability to induce systemic and tissue-specific memory CD8+ T cells. This vaccine shows promise in enhancing cellular immunity against SARS-CoV-2, potentially benefiting high-risk populations, such as the elderly and immunocompromised individuals. It demonstrates significant increases in CD8+ T-cell frequency and robust immune response against the Spike protein of the virus. The findings suggest a potential for durable protection against reinfection.
Heat Biologics (NASDAQ: HTBX) announced preclinical results for its gp96-based COVID-19 vaccine, showing a robust T cell immune response after a single dose. Developed at the University of Miami, the vaccine triggered the expansion of CD8+ and CD4+ T cells, which are essential for combating SARS-CoV-2. CEO Jeff Wolf emphasized the potential of their vaccine in enhancing efficacy when used alone or alongside existing vaccines. The company plans to publish full study details soon, while continuing to advance other product candidates in its pipeline.
Heat Biologics (NASDAQ:HTBX) announced promising preclinical data for its gp96-based COVID-19 vaccine, demonstrating robust T cell-driven immune responses against SARS-CoV-2. Conducted at the University of Miami, the study showed significant expansion of CD8+ and CD4+ T cells following a single dose, enhancing the anti-viral immune response. The CEO expressed optimism about the vaccine's unique capability to generate T cell immunity, potentially allowing it to complement existing vaccine approaches. Further details of the study are expected soon.